Triple-Negative Breast Cancer Research and Education Act of 2025
Summary
HR1806 is a procedural, early-stage House bill that directs federal research and education efforts for triple-negative breast cancer but authorizes no specific funding, creates no procurement programs, and imposes no mandates on public companies. It has zero immediate market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR1806 is an authorization-only bill with zero appropriated funding — no money trail exists.
- 2.The bill has been inactive in committee for 13 months with no legislative momentum.
- 3.No public company is referenced or structurally affected by this bill's provisions.
- 4.Retail investors should disregard this event entirely for portfolio decisions.
Market Implications
No market implications. This bill does not affect revenue, costs, or competitive positioning for any publicly traded company. The legislation is procedural and stalled. Investors should not allocate capital based on this event.
Full Analysis
-
What happened: On March 3, 2025, Rep. Morelle (D-NY) introduced HR1806, the Triple-Negative Breast Cancer Research and Education Act of 2025. The bill was referred to the House Committee on Energy and Commerce — its first and only action to date. It remains in early-stage committee review with no further legislative activity in the 13 months since introduction.
-
The money trail: The bill authorizes NO specific funding amount. It directs the Secretary of Health and Human Services to expand research and public education programs through existing NIH/CDC authorities, but does not appropriate any new money. This is a classic authorization-only bill — any actual spending would require a separate appropriations bill. Since no funding is authorized, there is no procurement mechanism, no grant program with a dollar figure, and no revenue stream created for any company.
-
Structural winners and losers: There are none. The bill neither names any company nor creates a mechanism that would differentially affect any publicly traded entity. Potential future beneficiaries of expanded research funding (e.g., diagnostic companies like $EXAS, $GH, or $ILMN) are not mentioned, and the bill does not establish a program from which they could directly contract. Without a funding authorization, there is no binding commitment.
-
Competitive landscape: No market data is provided or relevant. The bill has zero structural impact on competitive positioning in the healthcare sector.
-
Timeline: The bill has been stalled in committee for over a year with no hearings, markups, or companion Senate bill. With only 12 cosponsors and a sponsor who is a junior member (not a committee chair), passage in its current form is unlikely in the 119th Congress. The typical path would require committee hearings, a floor vote, Senate introduction and passage, and presidential signature — all absent here.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Reducing Hereditary Cancer Act
PREEMIE Reauthorization Act of 2025
Genomic Answers for Children’s Health Act of 2026
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Benay Taub Lung Cancer Research Act
To support biotechnology education for secondary school students, and for other purposes.
MERCK SHARP & DOHME LLC: $2.4B Department of Health and Human Services Contract Vehicle
PA DEPARTMENT OF HUMAN SERVICES: $1.0B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →